Business Context and Reporting Period
This Form 8-K Current Report was filed by Dermata Therapeutics, Inc. on June 7, 2024. The Company, a Delaware corporation and emerging growth company, reported the entry into a material definitive agreement to facilitate the sale of its common stock.
Key Financial Metrics and Agreement Terms
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the new financing arrangement:
- Agreement Type: At The Market (ATM) Offering Agreement.
- Counterparty: H.C. Wainwright & Co., LLC (Sales Agent).
- Securities Eligible for Sale: Common Stock, par value $0.0001 per share (Trading Symbol: DRMA).
- Aggregate Market Value Eligible: $1,157,761 (based on Form S-3 limitations).
- Commission Rate: 3.0% of the gross sales price of shares sold.
- Expense Reimbursement Cap: Up to $70,000 for specified expenses, plus $5,000 per annual and $2,500 per quarterly due diligence session updates.
Material Changes
The material change reported is the execution of the ATM Agreement on June 7, 2024. This agreement enables the Company to sell shares of common stock from time to time through the Sales Agent, subject to market conditions and Company instructions. The Company retains the right to suspend offers at any time and has no obligation to sell any shares.
Guidance, Outlook, and Risks
Management Commentary: The Company will set parameters for sales, including share count, timing, daily limits, and minimum price thresholds. Sales may occur directly on the Nasdaq Capital Market or via privately negotiated transactions with prior approval.
Risks and Contingencies:
- The Sales Agent is not obligated to purchase shares on a principal basis.
- Sales are subject to the effectiveness of the underlying Registration Statement (File No. 333-268383).
- The offering will terminate upon the sale of all eligible shares or earlier termination by either party.
- The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of DRMA to assess the potential dilution impact of the $1,157,761 offering limit.
- Review the full text of the ATM Agreement (Exhibit 1.1) for specific conditions precedent and termination rights.
- Monitor future 10-Q and 10-K filings for actual sales volumes and proceeds generated under this agreement.
- Confirm the Company's cash runway and liquidity position in recent quarterly reports, as this ATM facility is a potential source of future capital.